See more : Insight Acquisition Corp. (INAQ) Income Statement Analysis – Financial Results
Complete financial analysis of Exelixis, Inc. (EXEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Exelixis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Evogene Ltd. (EVGN) Income Statement Analysis – Financial Results
- Suncha Technology Co., Ltd. (001211.SZ) Income Statement Analysis – Financial Results
- PT PP Presisi Tbk (PPRE.JK) Income Statement Analysis – Financial Results
- Quanergy Systems, Inc. (QNGYQ) Income Statement Analysis – Financial Results
- Real Luck Group Ltd. (LUKEF) Income Statement Analysis – Financial Results
Exelixis, Inc. (EXEL)
About Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.83B | 1.61B | 1.43B | 987.54M | 967.78M | 853.83M | 452.48M | 191.45M | 37.17M | 25.11M | 31.34M | 47.45M | 289.64M | 185.05M | 151.76M | 117.86M | 113.47M | 98.67M | 75.96M | 52.86M | 51.54M | 44.32M | 41.01M | 24.76M | 10.50M | 2.27M |
| Cost of Revenue | 72.55M | 57.91M | 52.87M | 36.27M | 33.10M | 26.35M | 15.07M | 6.55M | 3.90M | 2.04M | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 202.00K | 820.00K | 1.09M | 779.00K | 0.00 | 0.00 | 0.00 | -18.60M | -5.70M | 0.00 |
| Gross Profit | 1.76B | 1.55B | 1.38B | 951.27M | 934.68M | 827.48M | 437.41M | 184.90M | 33.28M | 23.07M | 30.22M | 47.45M | 289.64M | 185.05M | 151.76M | 117.86M | 113.27M | 97.85M | 74.88M | 52.08M | 51.54M | 44.32M | 41.01M | 43.36M | 16.20M | 2.27M |
| Gross Profit Ratio | 96.04% | 96.41% | 96.32% | 96.33% | 96.58% | 96.91% | 96.67% | 96.58% | 89.52% | 91.86% | 96.43% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.82% | 99.17% | 98.57% | 98.53% | 100.00% | 100.00% | 100.00% | 175.11% | 154.29% | 100.00% |
| Research & Development | 1.04B | 891.81M | 693.72M | 547.85M | 336.96M | 182.26M | 112.17M | 95.97M | 96.35M | 189.10M | 178.76M | 128.88M | 156.84M | 210.68M | 234.70M | 257.39M | 225.38M | 185.48M | 141.14M | 137.72M | 127.62M | 112.01M | 82.70M | 48.46M | 21.70M | 12.10M |
| General & Administrative | 502.71M | 418.26M | 369.92M | 268.26M | 210.34M | 206.37M | 159.36M | 116.15M | 57.31M | 50.83M | 50.96M | 31.84M | 33.13M | 33.02M | 0.00 | 36.89M | 44.94M | 39.12M | 27.73M | 20.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 40.00M | 41.60M | 31.80M | 25.10M | 17.90M | 14.80M | 8.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 542.71M | 459.86M | 401.72M | 293.36M | 228.24M | 206.37M | 159.36M | 116.15M | 57.31M | 50.83M | 50.96M | 31.84M | 33.13M | 33.02M | 38.96M | 36.89M | 44.94M | 39.12M | 27.73M | 20.91M | 18.59M | 18.76M | 19.17M | 18.91M | 7.60M | 5.47M |
| Other Expenses | 0.00 | -197.00K | -184.00K | 912.00K | 680.00K | 397.00K | -3.54M | 7.47M | 0.00 | 9.64M | 2.35M | 9.17M | 10.14M | 32.74M | 0.00 | 41.46M | 82.08M | 39.94M | 28.82M | 21.68M | 19.25M | 19.42M | 26.95M | 37.76M | 13.30M | 5.47M |
| Operating Expenses | 1.59B | 1.35B | 1.10B | 841.21M | 565.21M | 388.62M | 271.53M | 212.11M | 153.66M | 239.93M | 229.72M | 160.72M | 189.97M | 243.70M | 273.67M | 298.85M | 307.45M | 225.42M | 169.95M | 159.41M | 146.87M | 131.44M | 109.65M | 86.22M | 35.00M | 17.57M |
| Cost & Expenses | 1.66B | 1.41B | 1.15B | 877.48M | 598.31M | 414.97M | 286.60M | 218.66M | 157.55M | 241.97M | 230.84M | 160.72M | 189.97M | 243.70M | 273.67M | 298.85M | 307.45M | 225.42M | 169.95M | 159.41M | 146.87M | 131.44M | 109.65M | 67.62M | 29.30M | 17.57M |
| Interest Income | 86.54M | 33.07M | 7.67M | 19.87M | 27.96M | 12.84M | 4.88M | 4.86M | 412.00K | 4.34M | 1.22M | 1.99M | 1.46M | 138.00K | 1.51M | 5.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.68M | 33.06M | 48.67M | 48.61M | 45.35M | 27.09M | 16.26M | 9.34M | 12.67M | 6.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.72M | 20.88M | 13.63M | 13.97M | 11.17M | 7.77M | 1.19M | 1.00M | 1.41M | 2.39M | 3.15M | 5.72M | 6.82M | 10.54M | 12.60M | 13.23M | 11.33M | 16.91M | 17.76M | 17.49M | 17.75M | 16.70M | 15.21M | 18.86M | 5.70M | 0.00 |
| EBITDA | 196.60M | 222.36M | 300.30M | 110.06M | 369.47M | 438.86M | 168.30M | -36.16M | -119.60M | -217.73M | -196.36M | -114.73M | 100.07M | -72.52M | -115.58M | -155.58M | -157.05M | -109.84M | -70.87M | -89.06M | -77.59M | -70.41M | -53.43M | -24.01M | -13.10M | -15.30M |
| EBITDA Ratio | 10.74% | 12.51% | 19.98% | 11.14% | 38.18% | 52.95% | 36.96% | -11.67% | -322.73% | -846.33% | -632.71% | -222.47% | 34.92% | -25.92% | -79.33% | -143.77% | -193.52% | -111.32% | -100.36% | -114.48% | -149.90% | -157.86% | -107.47% | 56.90% | -124.76% | -673.24% |
| Operating Income | 170.89M | 201.48M | 286.67M | 110.06M | 369.47M | 438.86M | 165.91M | -28.12M | -121.42M | -224.46M | -200.73M | -122.44M | 89.54M | -91.40M | -121.91M | -179.31M | -157.05M | -126.75M | -93.99M | -135.20M | -96.26M | -87.82M | -75.31M | -42.86M | -18.80M | -15.30M |
| Operating Income Ratio | 9.34% | 12.51% | 19.98% | 11.14% | 38.18% | 51.40% | 36.67% | -14.69% | -326.65% | -893.86% | -640.54% | -258.03% | 30.91% | -49.39% | -80.33% | -152.14% | -138.40% | -128.46% | -123.74% | -255.79% | -186.77% | -198.15% | -183.67% | -173.12% | -179.05% | -673.24% |
| Total Other Income/Expenses | 86.64M | 32.87M | 7.49M | 20.78M | 28.64M | 13.24M | -7.33M | -42.10M | -40.27M | -44.27M | -44.12M | -25.10M | -12.54M | -1.01M | -18.94M | 3.74M | 46.03M | 25.26M | -819.00K | -2.04M | 1.14M | 3.29M | -9.36M | -38.09M | 0.00 | -370.00K |
| Income Before Tax | 257.52M | 234.35M | 294.15M | 130.84M | 398.11M | 452.09M | 158.58M | -70.22M | -169.68M | -268.72M | -244.86M | -147.54M | 76.99M | -92.40M | -140.84M | -162.85M | -86.38M | -101.49M | -94.81M | -137.25M | -95.12M | -84.53M | -84.68M | -80.96M | 0.00 | -15.67M |
| Income Before Tax Ratio | 14.07% | 14.55% | 20.50% | 13.25% | 41.14% | 52.95% | 35.05% | -36.68% | -456.48% | -1,070.14% | -781.34% | -310.93% | 26.58% | -49.93% | -92.81% | -138.18% | -76.13% | -102.86% | -124.81% | -259.65% | -184.55% | -190.73% | -206.50% | -326.98% | 0.00% | -689.52% |
| Income Tax Expense | 49.76M | 52.07M | 63.09M | 19.06M | 77.10M | -237.98M | 4.35M | 32.06M | 55.00K | -182.00K | -96.00K | 107.00K | 1.30M | -72.00K | -1.29M | -18.14M | -107.60M | 0.00 | -9.59M | 30.69M | -345.00K | 345.00K | 2.55M | 32.45M | -100.00K | 0.00 |
| Net Income | 207.77M | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M | 154.23M | -70.22M | -169.74M | -268.54M | -244.76M | -147.65M | 75.70M | -92.33M | -135.22M | -162.85M | -86.38M | -101.49M | -84.40M | -137.25M | -94.77M | -86.13M | -71.19M | -75.31M | -18.70M | -15.67M |
| Net Income Ratio | 11.35% | 11.31% | 16.10% | 11.32% | 33.17% | 80.82% | 34.09% | -36.68% | -456.63% | -1,069.42% | -781.03% | -311.16% | 26.14% | -49.90% | -89.10% | -138.18% | -76.13% | -102.86% | -111.11% | -259.65% | -183.88% | -194.33% | -173.60% | -304.18% | -178.10% | -689.52% |
| EPS | 0.65 | 0.57 | 0.73 | 0.36 | 1.06 | 2.32 | 0.52 | -0.28 | -0.81 | -1.38 | -1.33 | -0.92 | 0.60 | -0.85 | -1.26 | -1.54 | -0.87 | -1.17 | -1.07 | -1.89 | -1.45 | -1.52 | -1.53 | -2.43 | -4.60 | -7.88 |
| EPS Diluted | 0.65 | 0.56 | 0.72 | 0.35 | 1.02 | 2.21 | 0.49 | -0.28 | -0.81 | -1.38 | -1.33 | -0.92 | 0.58 | -0.85 | -1.26 | -1.54 | -0.87 | -1.17 | -1.07 | -1.89 | -1.45 | -1.52 | -1.53 | -2.43 | -4.60 | -7.88 |
| Weighted Avg Shares Out | 318.15M | 321.53M | 314.88M | 308.27M | 302.58M | 297.89M | 293.59M | 250.53M | 209.23M | 194.30M | 184.03M | 160.14M | 126.02M | 108.52M | 107.07M | 105.50M | 99.15M | 86.60M | 78.81M | 72.50M | 65.39M | 56.62M | 46.49M | 31.03M | 4.07M | 1.99M |
| Weighted Avg Shares Out (Dil) | 321.46M | 324.56M | 322.36M | 318.00M | 315.01M | 312.80M | 312.00M | 250.53M | 209.23M | 194.30M | 184.06M | 160.14M | 130.48M | 108.52M | 107.07M | 105.50M | 99.15M | 86.60M | 78.81M | 72.50M | 65.39M | 56.62M | 46.49M | 31.03M | 4.07M | 1.99M |
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
Exelixis (EXEL) International Revenue Performance Explored
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript
Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
The Top 3 Biotech Stocks to Buy in April 2024
Source: https://incomestatements.info
Category: Stock Reports